Herceptin

Metastatic breast cancer
Herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours
that overexpress HER2:

• as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; or
• in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or
• in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic
• breast cancer.
   

Early breast cancer
Herceptin is indicated for the treatment of patients with:
 

• HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy,
• followed by adjuvant Herceptin; or
• HER2-positive early breast cancer following surgery, sequentially or concurrently with chemotherapy and, if applicable, radiotherapy.
• Herceptin should only be used in early breast cancer patients with a normal left ventricular ejection
• fraction.

Advanced gastric cancer
Herceptin is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.